Cargando…

Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019

This cross-sectional analysis aimed to assess the extent of conflicts of interest among the Japanese government coronavirus disease 2019 (COVID-19) advisory board members and elucidate the accuracy of conflicts of interest (COI) disclosure and management strategies. Using the payment data from all 7...

Descripción completa

Detalles Bibliográficos
Autores principales: Mamada, Hanano, Murayama, Anju, Ozaki, Akihiko, Hashimoto, Takanao, Saito, Hiroaki, Sawano, Toyoaki, Yamashita, Erika, Bhandari, Divya, Shrestha, Sunil, Tanimoto, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875957/
https://www.ncbi.nlm.nih.gov/pubmed/36705373
http://dx.doi.org/10.1097/MD.0000000000032776
_version_ 1784878061505740800
author Mamada, Hanano
Murayama, Anju
Ozaki, Akihiko
Hashimoto, Takanao
Saito, Hiroaki
Sawano, Toyoaki
Yamashita, Erika
Bhandari, Divya
Shrestha, Sunil
Tanimoto, Tetsuya
author_facet Mamada, Hanano
Murayama, Anju
Ozaki, Akihiko
Hashimoto, Takanao
Saito, Hiroaki
Sawano, Toyoaki
Yamashita, Erika
Bhandari, Divya
Shrestha, Sunil
Tanimoto, Tetsuya
author_sort Mamada, Hanano
collection PubMed
description This cross-sectional analysis aimed to assess the extent of conflicts of interest among the Japanese government coronavirus disease 2019 (COVID-19) advisory board members and elucidate the accuracy of conflicts of interest (COI) disclosure and management strategies. Using the payment data from all 79 pharmaceutical companies in Japan between 2017 and 2019 and direct research grants from the Japanese government between 2019 and 2020, we evaluated the extent of financial and non-financial COI among all 20 Japanese government COVID-19 advisory board members. The Ethic Committee of the Medical Governance Research Institute approved this study. Japanese government COVID-19 advisory board members were predominantly male (75.0%) and physicians (50.0%). Between 2019 and 2020, 2 members (10.0%) received a total of $819,244 in government research funding. Another 5 members (25.0%) received $532,127 in payments, including $276,722 in personal fees, from 31 pharmaceutical companies between 2017 and 2019. The average value of the pharmaceutical payments was $9155 (standard deviation: $12,975). Furthermore, neither the Ministry of Health, Labor, and Welfare nor the Japanese Cabinet Secretariat disclosed financial or non-financial COI with industry. Additionally, the government had no policies for managing COI among advisory board members. This study found that the Japanese government COVID-19 advisory board had financial and non-financial COI with pharmaceutical companies and the government. Furthermore, personal communication received as part of this research indicated that there were no rigorous COI management strategies for the COVID-19 advisory board members. Any government must ensure the independence of scientific advisory boards by implementing more rigorous and transparent management strategies that require the declaration and public disclosure of all COI.
format Online
Article
Text
id pubmed-9875957
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-98759572023-01-27 Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019 Mamada, Hanano Murayama, Anju Ozaki, Akihiko Hashimoto, Takanao Saito, Hiroaki Sawano, Toyoaki Yamashita, Erika Bhandari, Divya Shrestha, Sunil Tanimoto, Tetsuya Medicine (Baltimore) 6600 This cross-sectional analysis aimed to assess the extent of conflicts of interest among the Japanese government coronavirus disease 2019 (COVID-19) advisory board members and elucidate the accuracy of conflicts of interest (COI) disclosure and management strategies. Using the payment data from all 79 pharmaceutical companies in Japan between 2017 and 2019 and direct research grants from the Japanese government between 2019 and 2020, we evaluated the extent of financial and non-financial COI among all 20 Japanese government COVID-19 advisory board members. The Ethic Committee of the Medical Governance Research Institute approved this study. Japanese government COVID-19 advisory board members were predominantly male (75.0%) and physicians (50.0%). Between 2019 and 2020, 2 members (10.0%) received a total of $819,244 in government research funding. Another 5 members (25.0%) received $532,127 in payments, including $276,722 in personal fees, from 31 pharmaceutical companies between 2017 and 2019. The average value of the pharmaceutical payments was $9155 (standard deviation: $12,975). Furthermore, neither the Ministry of Health, Labor, and Welfare nor the Japanese Cabinet Secretariat disclosed financial or non-financial COI with industry. Additionally, the government had no policies for managing COI among advisory board members. This study found that the Japanese government COVID-19 advisory board had financial and non-financial COI with pharmaceutical companies and the government. Furthermore, personal communication received as part of this research indicated that there were no rigorous COI management strategies for the COVID-19 advisory board members. Any government must ensure the independence of scientific advisory boards by implementing more rigorous and transparent management strategies that require the declaration and public disclosure of all COI. Lippincott Williams & Wilkins 2023-01-27 /pmc/articles/PMC9875957/ /pubmed/36705373 http://dx.doi.org/10.1097/MD.0000000000032776 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 6600
Mamada, Hanano
Murayama, Anju
Ozaki, Akihiko
Hashimoto, Takanao
Saito, Hiroaki
Sawano, Toyoaki
Yamashita, Erika
Bhandari, Divya
Shrestha, Sunil
Tanimoto, Tetsuya
Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019
title Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019
title_full Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019
title_fullStr Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019
title_full_unstemmed Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019
title_short Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019
title_sort observational study of financial and non-financial conflicts of interest among the japanese government advisory board members concerning coronavirus disease 2019
topic 6600
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875957/
https://www.ncbi.nlm.nih.gov/pubmed/36705373
http://dx.doi.org/10.1097/MD.0000000000032776
work_keys_str_mv AT mamadahanano observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019
AT murayamaanju observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019
AT ozakiakihiko observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019
AT hashimototakanao observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019
AT saitohiroaki observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019
AT sawanotoyoaki observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019
AT yamashitaerika observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019
AT bhandaridivya observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019
AT shresthasunil observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019
AT tanimototetsuya observationalstudyoffinancialandnonfinancialconflictsofinterestamongthejapanesegovernmentadvisoryboardmembersconcerningcoronavirusdisease2019